These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

585 related items for PubMed ID: 24755449

  • 1. [Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
    Simonyi G.
    Orv Hetil; 2014 Apr 27; 155(17):669-75. PubMed ID: 24755449
    [Abstract] [Full Text] [Related]

  • 2. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.
    Krempf M, Simpson RJ, Ramey DR, Brudi P, Giezek H, Tomassini JE, Lee R, Farnier M.
    Lipids Health Dis; 2015 May 19; 14():45. PubMed ID: 25985907
    [Abstract] [Full Text] [Related]

  • 3. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P, IN-PRACTICE study.
    Int J Clin Pract; 2010 Jul 19; 64(8):1052-61. PubMed ID: 20487050
    [Abstract] [Full Text] [Related]

  • 4. Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
    Kurabayashi M, Yamazaki T, SUBARU Study Group.
    J Atheroscler Thromb; 2008 Dec 19; 15(6):314-23. PubMed ID: 19060425
    [Abstract] [Full Text] [Related]

  • 5. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM, Penning-van Beest FJ, Plat AW, Meerding WJ, Webb K, Sturkenboom MC, Herings RM.
    Pharmacotherapy; 2012 Jul 19; 32(7):631-41. PubMed ID: 22760692
    [Abstract] [Full Text] [Related]

  • 6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov 19; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 7. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
    Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Davidson MH.
    Clin Ther; 2007 Nov 19; 29(11):2385-94. PubMed ID: 18158079
    [Abstract] [Full Text] [Related]

  • 8. [One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].
    Simonyi G, Ferenci T.
    Orv Hetil; 2016 Mar 13; 157(11):425-9. PubMed ID: 26947091
    [Abstract] [Full Text] [Related]

  • 9. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis.
    Middleton A, Binbrek AS, Fonseca FA, Wilpshaar W, Watkins C, Strandberg TE.
    Curr Med Res Opin; 2006 Jun 13; 22(6):1181-91. PubMed ID: 16846551
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 13; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 12. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
    Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ.
    Am J Cardiol; 2010 Jan 01; 105(1):69-76. PubMed ID: 20102893
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
    Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F, ECLIPSE Study Investigators.
    Cardiology; 2008 Jan 01; 111(4):219-28. PubMed ID: 18434729
    [Abstract] [Full Text] [Related]

  • 14. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
    Shioji K, Izuhara M, Mitsuoka H, Uegaito T, Matsuda M, Kishiwada Atherosclerosis Prevention Study (KAPS) Group.
    Cardiovasc Ther; 2014 Jun 01; 32(3):97-104. PubMed ID: 24456217
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 01; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs. reality.
    Bożentowicz-Wikarek M, Kocełak P, Smertka M, Olszanecka-Glinianowicz M, Chudek J.
    Pharmacol Rep; 2012 Sep 01; 64(2):377-85. PubMed ID: 22661189
    [Abstract] [Full Text] [Related]

  • 18. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
    Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ.
    Lancet; 2015 Aug 01; 386(9992):452-60. PubMed ID: 26047975
    [Abstract] [Full Text] [Related]

  • 19. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS).
    Goodman SG, Langer A, Bastien NR, McPherson R, Francis GA, Genest JJ, Leiter LA, DYSIS Canadian Investigators.
    Can J Cardiol; 2010 Nov 01; 26(9):e330-5. PubMed ID: 21076724
    [Abstract] [Full Text] [Related]

  • 20. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
    Edwards JE, Moore RA.
    BMC Fam Pract; 2003 Dec 01; 4():18. PubMed ID: 14969594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.